SpinalCyte announces sustained 12-month MRI outcomes after CybroCell injection

346

SpinalCyte logo

SpinalCyte has announced that a single injection of modified human dermal fibroblasts (HDFs) resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD).

The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell or CybroCell with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection.

Analysed individually, 83% of spinal discs that were injected with CybroCell had an increase or no change in disc height compared to 25% of saline injected discs. The 12-month MRI data from the landmark Phase 1/Phase 2 trial were analysed for 17 patients by an independent radiological expert.

“Verification of structural improvements via MRI at 6- and 12-months strongly suggests that we are inducing a biological cascade of events associated with the induction of a regenerative process in the patient,” said Jesus Perez, principal investigator of the clinical trial. “Based on the clinical observations, imaging studies and patient testimonies, I believe that CybroCell is a breakthrough in the treatment of DDD.”

As previously reported, after 6 and 12 months, more than 90% of the treatment group had over a 10-point reduction in Oswestry Disability Index (ODI) and 100% had improvement in Visual Analogue Scale (VAS). On average, treatment group patients showed a 59% improvement in ODI scores, compared to the 22% improvement in the placebo group.

“The MRI image study demonstrates that a single injection of CybroCell leads to persistent structural and functional improvement in patients with DDD over a year,” said SpinalCyte chief scientific officer, Thomas Ichim. “To my knowledge, the pain and MRI data are clearly superior to all other reported cell therapy trial data for DDD. Developing solutions which target and treat the source of chronic pain for patients with DDD, a population which today accounts for about 50% of prescription opioid usage, has implications in combating the opioid epidemic.”

SpinalCyte’s Phase 1/Phase 2 clinical trial is the first allogeneic use of fibroblasts outside of skin conditions. CybroCell is based on research showing that skin derived cells are capable of healing the disc as previously reported in The Spine Journal.

“There are limited options to treat the pain in patients with DDD and no treatments that can regrow the spinal disc,” said SpinalCyte chief executive officer, Pete O’Heeron. “With the positive 12-month data from our trial, SpinalCyte is positioned at the forefront of this emerging sector of fibroblast-based cell therapies. In contrast to stem cells, which are difficult and costly to procure and develop into a drug, CybroCell uses fibroblasts which are found in large numbers and are already approved by the FDA for treatment of skin conditions.”

(Visited 272 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here